Abstract
Remyelination efficiency declines with advancing age in animal models, but this has been harder to demonstrate in people with multiple sclerosis. We show that bexarotene, a putatively remyelinating retinoid-X receptor agonist, shortened the visual evoked potential latency in patients with chronic optic neuropathy aged under 42 years only (with the effect diminishing by 0.45 ms per year of age); and increased the magnetization transfer ratio of deep gray matter lesions in those under 43 years only. Addressing this age-related decline in human remyelination capacity will be an important step in the development of remyelinating therapies that work across the lifespan.
© 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
MeSH terms
-
Age Factors
-
Aged
-
Animals
-
Bexarotene* / pharmacology
-
Bexarotene* / therapeutic use
-
Evoked Potentials, Visual / drug effects
-
Evoked Potentials, Visual / physiology
-
Humans
-
Multiple Sclerosis / complications
-
Multiple Sclerosis / drug therapy
-
Multiple Sclerosis / physiopathology
-
Optic Nerve Diseases* / drug therapy
-
Optic Nerve Diseases* / etiology
-
Optic Nerve Diseases* / physiopathology
-
Peripheral Nervous System Agents* / pharmacology
-
Peripheral Nervous System Agents* / therapeutic use
-
Remyelination* / drug effects
-
Remyelination* / physiology
-
Retinoid X Receptors* / administration & dosage
-
Retinoid X Receptors* / agonists
-
Retinoid X Receptors* / pharmacology
-
Retinoids / administration & dosage
-
Retinoids / pharmacology
Substances
-
Peripheral Nervous System Agents
-
Retinoid X Receptors
-
Retinoids
-
Bexarotene